Cipla Ltd (CIPLA)
Healthcare · Pharmaceuticals · NSE · Updated 1 October 2026
₹1,383↓ 7.9% (1Y)
🎯 Key Takeaways
- Revenue grew 8.8% QoQ to ₹7,119 in Q1FY27.
- Market Cap
- ₹1.12 L Cr
- P/E Ratio
- 33.1
- P/B Ratio
- 3.24
- ROE
- 9.8%
- ROCE
- 13.2%
- Debt/Equity
- 0.01
- Div Yield
- 0.94%
- Promoter
- 29.2%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 7,589 | 7,074 | 6,541 | 7,119 |
| Operating Profit | 1,598 | 977 | 572 | 888 |
| OPM % | 21.1% | 13.8% | 8.8% | 12.5% |
| Net Profit | 1,353 | 675 | 550 | 787 |
| EPS | ₹16.73 | ₹8.37 | ₹6.87 | ₹9.77 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 162 | 162 | 162 | 162 |
| Reserves | 31,032 | 28,201 | 34,270 | 32,757 |
| Borrowings | 438 | 461 | 258 | 467 |
| Total Liabilities | 37,387 | 34,655 | 42,496 | 40,164 |
| Fixed Assets | 5,374 | 5,232 | 12,890 | 5,560 |
| Investments | 7,933 | 4,995 | 8,223 | 8,219 |
| Total Assets | 37,387 | 34,655 | 42,496 | 40,164 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +3,940 |
| Investing | -2,326 |
| Financing | -1,234 |
| Net Cash Flow | +380 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 29.2% | 29.2% | 29.2% | 29.2% |
| FII | 24.6% | 23.9% | 22.6% | 20.2% |
| DII | 30.2% | 30.7% | 32.0% | 34.6% |
| Public | 13.8% | 13.8% | 14.0% | 13.7% |
| # Shareholders | 5,34,587 | 5,40,521 | 5,84,217 | 5,78,679 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🟡 Board Meeting2026-09-28Cipla announced a board meeting on October 27, 2026, to approve unaudited financial results for the quarter and half year ended September 30, 2026, wi…
- 🔴 Corporate Action2026-09-24Cipla announced the allotment of 12,168 fully paid-up equity shares of INR 2 each under its ESOS 2013-A and ESAR 2021 schemes on 24 September 2026, in…
- 🔴 Announcement2026-09-22Cipla announced that Global Head Supply Chain Venkata Sai Mungara will transition to Chief of Manufacturing and Supply Chain Operations at Cipla USA I…
- 🔴 Announcement2026-09-18Cipla announced it received an ESG rating of 68 from Niche, a SEBI-registered provider, communicated to exchanges on September 11 and 17, 2026, and be…
- 🔴 Announcement2026-09-03Cipla announced an exclusive partnership with Qilu Pharmaceutical to license and supply a biosimilar version of Keytruda (pembrolizumab) in the United…
- 🔴 Announcement2026-09-03Cipla announced that following an NCLT order dated 18 August 2026, it is sending notices to shareholders and unsecured creditors of the proposed merge…
- 🔴 Announcement2026-08-31Cipla announced on August 31, 2026 that it signed an exclusive licensing agreement with SBP Group’s subsidiary CTTQ to develop and commercialize TQB21…
- 🔴 Announcement2026-08-28Cipla disclosed that the USFDA classified its Invagen manufacturing facility inspection in Central Islip, NY as Voluntary Action Indicated (VAI) on Au…
- 🔴 Announcement2026-08-27Cipla announced its schedule for upcoming analyst and institutional investor meetings in September 2026, including in-person sessions with Jefferies i…
- 🔴 Announcement2026-08-27Cipla announced a restructuring where Aspergen Limited, India acquired 100% of Aspergen Inc., USA from its subsidiaries, making the US entity a wholly…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when CIPLA files new disclosures
Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track CIPLA — FreeFree account · 2 AI queries/day